A members network for financial professionals and private investors. We keep our eyes focused on Nordic Tech and Life Science based companies with global reach.
Joined June 2010
- Tweets 22,079
- Following 254
- Followers 14,528
- Likes 768
13,229 Photos and videos
Redeye comments on InCoax announcing a SEK 11.2m directed share issue alongside an expanded credit facility, further strengthening its financial position.
$INCOAX
redeye.se/research/1172406/i…
1
452
Redeye comments on Faron's updated BEXMAB data presented at EHA 2026, which demonstrated continued maturation of the clinical and translational evidence supporting bexmarilimab in frontline high-risk MDS.
$FARON
redeye.se/research/1172391/f…
423
Model portfolio Top Picks has climbed almost 13% in three months – and we've just made three new transactions. Want to know what we bought, sold and why? Join our live Q&A via the link below.
redeye.se/research/1172226/t…
Top Picks is included in our premium memberships from SEK 349/month.
565
4C Group is trading below Redeye's Base Case. We spoke with our analyst about who the company's primary customers are, what the two business segments are, why 4C decided to place Resilience in harvest mode, and other key topics.
This is a premium article, included in our paid plans from SEK 99/month.
$4C
redeye.se/research/1172368/4…
465
Redeye har intervjuat IRLAB Therapeutics vd, Kristina Torfgård, och CFO, Gustaf Albèrt, om statusen i bolagets kliniska program, den pågående emissionen och målsättningar kring partnerskap framöver.
$IRLAB
redeye.se/research/1171936/i…
579
Redeye revisits the topline data from ADVANCE and, in this note, attempts to translate the results into an updated base case for SynAct Pharma.
$SYNACT
redeye.se/research/1172316/s…
463
Top Picks is back with an update. We have made three changes to the portfolio, leaving us fully invested once again.
Top Picks is included in our premium memberships from SEK 349/month.
redeye.se/research/1172226/t…
806
Redeye has interviewed SynAct Pharma's Mads Bjerregaard (CBO) and Thomas Jonassen (CSO) to discuss the ADVANCE topline data.
$SYNACT
redeye.se/research/1172206/s…
677
Redeye views the topline data as confirming a bell-shaped dose-response with resomelagon.
$SYNACT
redeye.se/research/1172191/s…
629
Redeye comments on Freemelt’s investor update on June 2nd shedding some light on the progress within the business verticals and the company’s path forward.
$FREEM
redeye.se/research/1170571/f…
2
730
Redeye comments on Magle announcing an update on the ongoing negotiations with its principal bondholders regarding a comprehensive refinancing and balance sheet restructuring.
$MAGLE
redeye.se/research/1172135/m…
714
Redeye comments on Xbrane partnering with California-based CDMO JOINN Biologics to advance CMC development of Xdarzane, its preclinical daratumumab biosimilar.
$XBRANE
redeye.se/research/1172089/x…
601
Redeye comments on Alzinova announcing today the successful outcome of the TO4 warrant exercise, completing the bridging financing package initiated with the rights issue earlier this year.
$ALZ
redeye.se/research/1172124/a…
1
614
Redeye has interviewed AAC’s CEO, Luis Gomes, following recent progress on the INFLECION program. We discussed the scope, addressed some details and the constellation's future potential.
$AAC
redeye.se/research/1172087/a…
520
Redeye reviews BioInvent’s second key opinion leader (KOL) event of 2026, highlighting clinical development updates for its two lead blood cancer candidates, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB).
$BINV
redeye.se/research/1172082/b…
1
518
Redeye has interviewed Better Collective’s CEO Jesper Søgaard and Gavin Moore who is head SVP of Paid Media.
$BETCO
redeye.se/research/1172077/b…
508
Nanologica is trading below Redeye's Base Case. We spoke with our analyst about what Syntagon is, and why Nanologica acquired it, what would cause Nanologica to require another equity raise, and other key topics.
This is a premium article, included in our paid plans from SEK 99/month.
$NICA
redeye.se/research/1171882/n…
564
Redeye adjusts its forecasts following the FDA's issuance of another complete response letter (CRL) for Camurus.
$CAMX
redeye.se/research/1171924/c…
759
Redeye provides its Q1 2026 update for the Swedish Quality Microcap theme.
Theme reports are part of our premium offering, starting at SEK 349/month.
Read the theme report:
redeye.se/research/1171743/r…
682
Redeye has interviewed VEF’s CEO, Dave Nangle. We discuss highlights from the company’s Q1 report, Creditas momentum, the latest developments in Konfío & Juspay and key focus areas for VEF in the coming quarters.
$VEF
redeye.se/research/1171862/v…
567